Learning outcomes
By the end of this lesson you should be able to: define affinity and intrinsic activity and distinguish an agonist, a partial agonist, a competitive antagonist and a non-competitive (insurmountable) antagonist; interpret a log dose-response curve and explain the meaning of EC50 and of Emax; state why antagonists shift agonist curves to the right and why some antagonists lower the maximum; explain the meaning of spare receptors; and predict the outcome of combining two drugs acting on the same receptor.
Prerequisites
Lesson 1 (What pharmacology is). You need the four receptor families and the principle that the receptor determines the effect.
The big idea
Binding a receptor and activating a receptor are two separate properties, and keeping them apart is the whole of this lesson. Affinity is how tightly a drug binds. Intrinsic activity is what happens when it does. Any combination of the two is possible, and the four combinations are the four drug classes: full agonist, partial agonist, antagonist, and the inverse agonist, which reduces the receptor's spontaneous activity.
The four classes of drug at a receptor
| Drug class | Affinity | Intrinsic activity | Effect on the receptor's own response |
|---|---|---|---|
| Full agonist | High | Full | Produces the maximal response of the system |
| Partial agonist | High | Partial | Produces a submaximal response — and can reduce the response to a full agonist |
| Antagonist (competitive) | High | None | Blocks the receptor; the agonist's curve shifts right, with the same maximum at high enough agonist |
| Antagonist (non-competitive, insurmountable) | High | None | Blocks the receptor in a way that more agonist cannot overcome, so the maximum response falls |
A partial agonist in the presence of a full agonist reduces the response — which seems paradoxical, and is the reason the distinction is examinated. A partial agonist occupies the receptor and produces only a sub-maximal response. Add a full agonist and the full agonist competes with the partial agonist for the same site; at high concentrations of the full agonist its maximal response is restored. So a partial agonist can be an agonist on its own and an antagonist in the presence of a full agonist — the behaviour that carved its niche in prescribing, as in the partial opioid agonist buprenorphine, which relieves pain but has a ceiling on respiratory depression.
Worked example: the log dose-response curve
The dose-response curve is plotted as the logarithm of dose against the response, and its three parameters are used in every drug comparison. The concentration that gives half the maximum effect is EC50, the smaller the concentration the more potent the drug. The maximum response is Emax, which is the measurement of efficacy — not how much drug was needed, but how much effect the system can achieve. And the slope reports cooperativity of binding, which can distinguish an allosteric interaction.
| Parameter | What it measures | Why it matters clinically |
|---|---|---|
| EC50 | The concentration producing half of Emax — the inverse of potency | The more potent drug needs a lower dose; a shift to the right after a competitive antagonist means more is needed for the same effect |
| Emax | The maximum response the system can produce | The measure of efficacy: a drug with a lower EC50 but a higher Emax may still be the better drug for a severe illness |
| Therapeutic index | The ratio TD50 to ED50 — toxic dose over effective dose | The safety margin: a wide index (penicillin) permits confident dosing; a narrow one (digoxin, lithium, phenytoin) requires monitoring |
NotePotency and efficacy are routinely confused and they are different. Potency is the dose needed; efficacy is the size of the response. A drug may be more potent but less efficacious, and if the illness needs a large response, efficacy wins.
Worked example: spare receptors
A maximal response in some tissues is achieved when only a fraction of the receptors are occupied. The remaining unoccupied receptors are the spare receptors. This explains how a tissue can respond to a tiny concentration of a drug when the receptor's affinity alone cannot account for it: the concentration at which half the receptors are occupied is not the same as the concentration at which the response is half-maximal.
The clinical consequence is the phenomenon of desensitisation. Remove some receptors from the membrane — by prolonged agonist exposure, by an autoimmune attack, or by a drug that down-regulates them — and a maximal response can still be produced if enough spare receptors remain. Tolerance, and the worsening response to repeated dosing in a patient with myasthenia gravis, both have the same molecular basis here.
Common mistakes
Watch outSaying competitive antagonism lowers the maximum response. It does not: adding enough agonist out-competes the antagonist and the maximum is restored. A fall in the maximum is non-competitive antagonism — or receptor down-regulation, which is a different mechanism.
Watch outSaying the therapeutic index is the ratio of the ED50 to the LD50. It is the TD50 to the ED50, with toxicity not mortality, and for the therapeutic window it describes the concentration range, not a dose ratio.
Watch outCalling an 'antagonist' a drug that has no effect. An antagonist can have a profound effect simply by blocking the receptor: naloxone in an opiate overdose, or flumazenil in a benzodiazepine overdose, both reverse otherwise fatal effects.
Check your understanding
What is the difference between a competitive and a non-competitive antagonist on a dose-response curve?
How can a partial agonist behave as an antagonist?
What is the therapeutic index of digoxin, and what does it mean for prescribing?
Multiple choice
What happens to the dose-response curve of a full agonist when a competitive antagonist is added?
Which of these describes a partial agonist?
Which statement about Emax is correct?
A drug has a therapeutic index of 2. How should it be prescribed relative to a drug with an index of 100?
Why is loss of spare receptors a clinical problem in disease?
Summary and next
At a receptor, a drug can be an agonist, a partial agonist or an antagonist depending on its intrinsic activity rather than its affinity, and a further split separates competitive antagonism — which shifts the curve right without lowering the maximum — from non-competitive antagonism, which lowers the maximum. Dose-response curves are compared by their EC50, a measure of potency, and by their Emax, a measure of efficacy. The therapeutic index, the ratio of toxic to effective dose, decides how carefully a drug must be monitored, and spare receptors buffer the consequences of receptor loss — until they are gone.
Next: pharmacokinetics, the other half. Once a drug is in the body, how does it get to the receptor, how much of it actually arrives, how long does it last, and how does the body get rid of it.